Hoong-Wei Gan1, Kim Phipps1, Kristian Aquilina1, Mark Nicholas Gaze1, Richard Hayward1, Helen Alexandra Spoudeas1. 1. Section for Genetics and Epigenetics in Health and Disease, Genetics and Genomic Medicine Programme (H.-W.G.), University College London Institute of Child Health, London WC1N 1EH, United Kingdom; The London Center for Pediatric Endocrinology & Diabetes (H.-W.G., H.A.S.), Great Ormond Street Hospital for Children NHS Foundation Trust, London WC1N 3JH, United Kingdom; Department of Neurosurgery (K.P., K.A., R.H.), Great Ormond Street Hospital for Children NHS Foundation Trust, London WC1N 3JH, United Kingdom; and Children and Young People's Cancer Services (M.N.G.), University College London Hospitals NHS Foundation Trust, London NW1 2PG, United Kingdom.
Abstract
CONTEXT: Fifty percent of pediatric low-grade gliomas affect the optic pathway, hypothalamus, and suprasellar areas (OP/HSGs), resulting in significant long-term neuroendocrinopathy. OBJECTIVE: This study aimed to dissect tumor- from treatment-related risk factors for OP/HSG-associated neuroendocrinopathy. DESIGN: This was a retrospective case notes analysis of 166 children with newly diagnosed OP/HSGs at our quaternary center between 1980 and 2010 by multivariate Cox, linear, and logistic regression. RESULTS: Patients were of median (range) age 4.9 (0.2-15.4) years at diagnosis and followed up for 8.3 (0.04-26.8) years. Despite high 20-year overall survival (81.0%), progression-free and endocrine event-free survival (EEFS) were 47.2 and 20.8%, respectively. EEFS declined up to 15 years post-diagnosis, with hypothalamic involvement (P < .001) being implicated more than radiotherapy (P = .008) in earlier endocrinopathy; the reverse being true of its density (radiotherapy P < .001; hypothalamic involvement P = .006). GH deficiency (GHD) was most common (40.3%), followed by central precocious puberty (CPP, 26.0%), gonadotropin (GnD; 20.4%), TSH (13.3%), and ACTH (13.3%) deficiencies. GHD increased with later treatment eras (P < .01), but replacement did not increase progression. CPP was associated with future GnD (P < .05). Posterior pituitary dysfunction (PPD; 7.2%) occurred in 57.9% after only biopsies or shunt procedures, and was associated with 6/13 deaths; 50.2% became obese. Tumor extent, surgery, and increased endocrinopathy, rather than radiotherapy, predicted visuocognitive morbidity. CONCLUSIONS: This first longitudinal OP/HSG-specific study demonstrates that hypothalamo-pituitary dysfunction evolves hierarchically over decades. Tumor location predicts its speed of onset and radiotherapy its density. GnD can evolve from previous CPP, whereas life-threatening PPD can occur after any surgery. Our data suggest that recent radiation-avoiding chemotherapeutic strategies have increased GHD without improving survival.
CONTEXT: Fifty percent of pediatric low-grade gliomas affect the optic pathway, hypothalamus, and suprasellar areas (OP/HSGs), resulting in significant long-term neuroendocrinopathy. OBJECTIVE: This study aimed to dissect tumor- from treatment-related risk factors for OP/HSG-associated neuroendocrinopathy. DESIGN: This was a retrospective case notes analysis of 166 children with newly diagnosed OP/HSGs at our quaternary center between 1980 and 2010 by multivariate Cox, linear, and logistic regression. RESULTS:Patients were of median (range) age 4.9 (0.2-15.4) years at diagnosis and followed up for 8.3 (0.04-26.8) years. Despite high 20-year overall survival (81.0%), progression-free and endocrine event-free survival (EEFS) were 47.2 and 20.8%, respectively. EEFS declined up to 15 years post-diagnosis, with hypothalamic involvement (P < .001) being implicated more than radiotherapy (P = .008) in earlier endocrinopathy; the reverse being true of its density (radiotherapy P < .001; hypothalamic involvement P = .006). GH deficiency (GHD) was most common (40.3%), followed by central precocious puberty (CPP, 26.0%), gonadotropin (GnD; 20.4%), TSH (13.3%), and ACTH (13.3%) deficiencies. GHD increased with later treatment eras (P < .01), but replacement did not increase progression. CPP was associated with future GnD (P < .05). Posterior pituitary dysfunction (PPD; 7.2%) occurred in 57.9% after only biopsies or shunt procedures, and was associated with 6/13 deaths; 50.2% became obese. Tumor extent, surgery, and increased endocrinopathy, rather than radiotherapy, predicted visuocognitive morbidity. CONCLUSIONS: This first longitudinal OP/HSG-specific study demonstrates that hypothalamo-pituitary dysfunction evolves hierarchically over decades. Tumor location predicts its speed of onset and radiotherapy its density. GnD can evolve from previous CPP, whereas life-threatening PPD can occur after any surgery. Our data suggest that recent radiation-avoiding chemotherapeutic strategies have increased GHD without improving survival.
Authors: Anthony P Y Liu; Camden Hastings; Shengjie Wu; Johnnie K Bass; Andrew M Heitzer; Jason Ashford; Robert Vestal; Mary E Hoehn; Yahya Ghazwani; Sahaja Acharya; Heather M Conklin; Frederick Boop; Thomas E Merchant; Amar Gajjar; Ibrahim Qaddoumi Journal: Cancer Date: 2019-01-08 Impact factor: 6.860
Authors: Peter M K de Blank; Michael J Fisher; Grant T Liu; David H Gutmann; Robert Listernick; Rosalie E Ferner; Robert A Avery Journal: J Neuroophthalmol Date: 2017-09 Impact factor: 3.042
Authors: Wassim Chemaitilly; Thomas E Merchant; Zhenghong Li; Nicole Barnes; Gregory T Armstrong; Kirsten K Ness; Ching-Hon Pui; Larry E Kun; Leslie L Robison; Melissa M Hudson; Charles A Sklar; Amar Gajjar Journal: Clin Endocrinol (Oxf) Date: 2015-11-16 Impact factor: 3.478
Authors: Laura van Iersel; Zhenghong Li; Deo Kumar Srivastava; Tara M Brinkman; Kari L Bjornard; Carmen L Wilson; Daniel M Green; Thomas E Merchant; Ching-Hon Pui; Rebecca M Howell; Susan A Smith; Gregory T Armstrong; Melissa M Hudson; Leslie L Robison; Kirsten K Ness; Amar Gajjar; Kevin R Krull; Charles A Sklar; Hanneke M van Santen; Wassim Chemaitilly Journal: J Clin Endocrinol Metab Date: 2019-12-01 Impact factor: 5.958
Authors: David T W Jones; Mark W Kieran; Eric Bouffet; Sanda Alexandrescu; Pratiti Bandopadhayay; Miriam Bornhorst; David Ellison; Jason Fangusaro; Michael J Fisher; Nicholas Foreman; Maryam Fouladi; Darren Hargrave; Cynthia Hawkins; Nada Jabado; Maura Massimino; Sabine Mueller; Giorgio Perilongo; Antoinette Y N Schouten van Meeteren; Uri Tabori; Katherine Warren; Angela J Waanders; David Walker; William Weiss; Olaf Witt; Karen Wright; Yuan Zhu; Daniel C Bowers; Stefan M Pfister; Roger J Packer Journal: Neuro Oncol Date: 2018-01-22 Impact factor: 12.300
Authors: Ciaran Scott Hill; Mehdi Khan; Kim Phipps; Katherine Green; Darren Hargrave; Kristian Aquilina Journal: Childs Nerv Syst Date: 2021-02-03 Impact factor: 1.475